<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560195</url>
  </required_header>
  <id_info>
    <org_study_id>HHPG-19K -III-02</org_study_id>
    <nct_id>NCT01560195</nct_id>
  </id_info>
  <brief_title>A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) on the Incidence of Neutropenia in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor
      to limit the dosage and the continuation of chemotherapy. A newly pegylated rhG-CSF was
      independently developed by JIANGSU HENGRUI Medicine Co., Ltd, China. Phase 1a, 1b and phase 2
      trials have shown that pegylated rhG-CSF has decreased renal clearance, increased plasma
      half-life, and prolonged efficacy in compare with ﬁlgrastim. The purpose of this study is to
      determine the safety and effectiveness of pegylated rhG-CSF in preventing neutropenia
      following chemotherapy in patients with advanced NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of grade 3/4 neutropenia in cycle 1</measure>
    <time_frame>21 days</time_frame>
    <description>the rate of ANC lower than 1.0 × 109/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia in cycle 1</measure>
    <time_frame>21 days</time_frame>
    <description>rate of ANC&lt;1.0×109/L and auxiliary temperature&gt;38.5℃</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of grade 3/4 neutropenia and incidence of febrile neutropenia in cycle 2 to 4</measure>
    <time_frame>Through 2 to 4 cycles</time_frame>
    <description>The rate of ANC lower than 1.0 × 109 /L and rate of ANC&lt;1.0×109/L and auxiliary temperature&gt;38.5℃</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil recovery in the 4 chemotherapy cycles</measure>
    <time_frame>Through 4 cycles</time_frame>
    <description>After chemotherapy administration the time from the expected nadir until the patient's ANC increased to 2.0 × 109/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of 3/4 neutropenia in the 4 chemotherapy cycles</measure>
    <time_frame>Through 4 cycles</time_frame>
    <description>duration of ANC lower than 1.0 × 109/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through 4 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress free survival</measure>
    <time_frame>Through 4 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through 4 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory biomarkers research</measure>
    <time_frame>Through 4 cycles</time_frame>
    <description>Relationship between SNP and microRNA with myelosuppression and tumor response rate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>NSCLC</condition>
  <condition>Neutropenia</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Pegylated rhG-CSF: 100µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Staged III or IV NSCLC patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegylated rhG-CSF: 6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Staged III or IV NSCLC patients receiving chemotherapy and pegylated rhG-CSF 6mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Staged III or IV NSCLC patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF in cycle 2 to 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated rhG-CSF: 100µg/kg</intervention_name>
    <description>Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.</description>
    <arm_group_label>Pegylated rhG-CSF: 100µg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated rhG-CSF: 6mg</intervention_name>
    <description>Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.</description>
    <arm_group_label>Pegylated rhG-CSF: 6mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo and rhG-CSF 5ug/kg/d</intervention_name>
    <description>Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Investigator diagnosis of staged III or IV NSCLC

          -  Age 18 to 70 years

          -  ECOG performance status ≤ 1

          -  Chemotherapy naïve

          -  Body weight ≥ 45kg

          -  Hemoglobin ≥ 100g/L; white blood cell ≥ 4.0×109/L; absolute neutrophil count ≥1.5 ×
             109/L; platelet count ≥ 100 × 109/L

          -  Alanine transarninase ≤1.5×ULN; aspartate aminotransferase ≤1.5×ULN; serum creatinine
             ≤1.5×ULN; total bilirubin ≤1.5×ULN

        Exclusion Criteria:

          -  History of systematic chemotherapy or radical radiation therapy

          -  Prior bone marrow or stem cell transplantation

          -  Received systemic antibiotics treatment within 72 h of chemotherapy

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caicun Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caicun Zhou, M. D.</last_name>
    <phone>862165115006</phone>
    <phone_ext>1053</phone_ext>
    <email>caicunzhou@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haoyuan Jiang, Ph. D.</last_name>
    <phone>862168868768</phone>
    <email>jianghy@shhrp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caicun Zhou, M. D.</last_name>
      <email>caicunzhou@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>November 4, 2012</last_update_submitted>
  <last_update_submitted_qc>November 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neutropenia</keyword>
  <keyword>febrile neutropenia</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

